Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety-related claims are supported (e.g., rhabdomyolysis, liver dysfunction/hepatic failure, memory impairment, peripheral neuropathy, liver enzyme abnormalities), but multiple claims are either unsupported or inaccurate relative to the provided label excerpts (e.g., “linked to liver cancer,” “can cause liver failure” as a causal statement, “on the market since 1997,” and “mechanism of action” statements phrased as beliefs). Indication/prevention claims are partially aligned but not fully supported as phrased.
Category Scores
Accurate Statements
Lipitor is also known as atorvastatin.
Label identifies LIPITOR as atorvastatin calcium (Drug/Active ingredient and/or mechanism section context).
Lipitor can be started simultaneously with diet in patients with CHD or multiple risk factors for CHD.
Section 1: “In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet.”
Lipitor has been linked to rhabdomyolysis.
Section 5.1: “Rare cases of rhabdomyolysis…” and Section 6.2: “rhabdomyolysis” listed in postmarketing experience.
Rhabdomyolysis is a rare but serious condition where muscle tissue breaks down, leading to kidney damage.
Section 5.1: rhabdomyolysis with acute renal failure secondary to myoglobinuria.
Lipitor has been linked to liver damage.
Section 5.2: biochemical abnormalities of liver function and contraindication for active liver disease/unexplained persistent transaminase elevations; Section 6.2 includes hepatic failure.
Lipitor has been linked to liver failure.
Section 6.2: “hepatic failure” reported since market introduction.
Some patients have reported cognitive impairment with Lipitor.
Section 6.2: “memory impairment” listed; “cognitive impairment” is consistent with memory impairment wording.
Cognitive impairment reported with Lipitor includes memory loss.
Section 6.2: “memory impairment.”
Lipitor has been linked to peripheral neuropathy.
Section 6.2: “peripheral neuropathy.”
Lipitor has been linked to muscle damage.
Section 5.1: myopathy/rhabdomyolysis; Section 6.1: “rhabdomyolysis and myopathy” discussed.
It is believed that Lipitor can cause muscle damage due to its mechanism of action.
Section 5.1 attributes increased risk with concomitant factors (CYP3A4 inhibitors, higher doses). Section 12.1 describes statin mechanism but does not explicitly state causality; however the general linkage to myopathy/rhabdomyolysis is label-supported.
Lipitor works by inhibiting the production of cholesterol in the liver.
Section 12.1: HMG-CoA reductase inhibition (cholesterol synthesis reduction).
Unsupported Statements
Lipitor is used to prevent heart disease.
Label excerpts specify reductions in risks of myocardial infarction, stroke, revascularization, angina, and other endpoints, but “prevent heart disease” is not stated verbatim in the provided label text.
Lipitor has been on the market since 1997.
No market introduction date is present in the provided label excerpts.
Lipitor has been linked to liver cancer.
“liver cancer” is not mentioned in the provided label excerpts.
Lipitor can cause liver failure.
Label lists “hepatic failure” as a postmarketing adverse reaction, but the claim is phrased as an unconditional causal capability; the provided excerpts do not explicitly state “can cause liver failure” as a general statement.
Cognitive impairment reported with Lipitor includes confusion.
“confusion” is not mentioned in the provided label excerpts (memory impairment is mentioned, but not confusion).
Peripheral neuropathy causes numbness, tingling, and pain in the hands and feet.
Symptom description of peripheral neuropathy is not provided in the supplied label excerpts.
Muscle damage linked to Lipitor includes muscle weakness.
Muscle weakness as a specific listed symptom is not included in the provided label excerpts.
Muscle damage linked to Lipitor includes muscle pain.
The label excerpt lists “myalgia” as a common reaction leading to discontinuation, which is muscle pain; however “muscle damage includes muscle pain” is not stated as such—this is a symptom implication not explicitly phrased in label.
The exact cause of the rare side effects of Lipitor is not fully understood.
No statement about whether the exact cause is fully understood is present in the provided label excerpts.
It is believed that Lipitor can cause liver damage due to its mechanism of action.
The label excerpts do not state that it is “believed” liver damage results from mechanism of action.
Contradictions
Important Omissions
For prevention use, label-supported endpoints should be stated (e.g., reduce risk of myocardial infarction, stroke, revascularization, angina; and in diabetes reduce MI and stroke).
Importance:
Moderate
If discussing safety, label-based contraindications/warnings are relevant (active liver disease, pregnancy, nursing; and monitoring of liver function tests and withholding/discontinuation guidance for suspected myopathy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety signals are label-supported (rhabdomyolysis, hepatic failure, memory impairment, peripheral neuropathy). However, unsupported/inaccurate claims (e.g., liver cancer; implied general causality statements; symptom descriptions not in label) could mislead risk perception. Provided excerpts do not support all phrasing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are not supported by the provided label excerpts (e.g., liver cancer; market since 1997; confusion; mechanism-based belief phrasing; some symptom/causality phrasing).
Suggested Improvement
Restrict claims to endpoints and adverse reactions explicitly present in the provided label excerpts, and avoid unsupported generalizations or symptom interpretations not stated in the label.